Tagged with Pharma,

India Mohal Sarabhai, a serial entrepreneur and grandson of the illustrious scientist and industrialist Vikram Sarabhai, provides insights into the eye-catching group of companies he has been developing over the past 15 years, ranging from the effervescent products specialist Vovantis to the fermentation-focused API manufacturer Synbiotics. He also documents his two-fold…

Portugal Paulo Teixeira shines a light on Pfizer’s promising pipeline for 2018, the market access environment in Portugal and the clinical trial landscape. Teixeira intends to contribute to improving society’s perception of the pharmaceutical industry and position Pfizer as a partner for health and wellbeing in Portugal; part of the solution—not…

UK After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back and analyses the new Mylan, while highlighting how it is fit for the future of healthcare. How does Mylan position…

Pharma While drug developers, healthcare practitioners and patients all rejoice at the advent of a golden age of scientific advancement in medicine – symbolized by recent radical breakthroughs in all manners of domains from stem cells and CAR-T generation immunotherapy to gene tech and 3D bio-printing – it is clear that…

Portugal Pedro Moura is the first Portuguese managing director of Merck in Portugal, taking on the role in September 2017 after a stint in HQ in Darmstadt, Germany. Moura discusses Merck’s global vision, new and exciting products coming soon to the Portuguese market and the importance of collaborative partnerships across the…

UK Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance of vaccine R&D and production in the UK.   We have a broad portfolio, from the very first vaccine that…

UK With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short period of time. Currently active in both the UK and Europe, EUSA is set to further expand internationally, notably in…

Portugal Azevedos is one of the oldest pharmaceutical brands in Portugal. Lead by Thebar Miranda, president for 30 years it operates across Portuguese speaking companies and distributes worldwide. In this interview, Miranda highlights the importance of flexibility and high-quality in production and sheds light on global production trends, Portugal’s status as…

Portugal Florian Ibe, managing director at Bayer Portugal, discusses market access hurdles, as well as Portugal’s expertise in scientific and clinical research and highly educated workforce. In three years of his tenure, Bayer has returned to growth, brought the global innovation portfolio to Portuguese patients and healthcare professionals in areas such…

Spain Humberto Arnés, director general at Farmaindustria, Spain’s leading pharmaceutical industry association, discusses the dynamics of the Spanish pharmaceutical industry showcasing a growth of 2.7 percent of the total public pharmaceutical expenditure while highlighting the association’s strategic plan, revolving around sustainability and access, transparency with healthcare professionals, an increase in industrial…

UK Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and drive change by enhancing productivity. With positive evolutions in the UK government’s approach to collaborative partnerships, he warns that clarity…

R&D With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald a flurry of mergers and acquisitions (M&As) within the pharma world. “Biotech and pharma M&A activity dropped to its lowest…